Herr, H. W. Role of repeat resection in non-muscle-invasive bladder cancer. J. Natl Compr. Cancer Netw. 13, 1041–1046 (2015).
Vianello, A. et al. Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis. J. Endourol. 25, 1703–1712 (2011).
Grimm, M.-O. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J. Urol. 170, 433–437 (2003).
Mariappan, P. et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int. 109, 1666–1673 (2012).
Samplaski, M. K. & Jones, J. S. Two centuries of cystoscopy: the development of imaging, instrumentation and synergistic technologies. BJU Int. 103, 154–158 (2009).
Herr H. W. Max Nitze, the cystoscope and urology. J. Urol. 176, 1313–1316 (2006).
Howard, J. M., Woldu, S. L., Daneshmand, S. & Lotan, Y. Enhanced endoscopy with IMAGE1 S CHROMA improves detection of nonmuscle invasive bladder cancer during transurethral resection. J. Endourol. 35, 647–651 (2021).
Shkolyar, E. et al. Augmented bladder tumor detection using deep learning. Eur. Urol. 76, 714–718 (2019).
Article PubMed PubMed Central Google Scholar
Akand, M. et al. Quality control indicators for transurethral resection of non-muscle-invasive bladder cancer. Clin. Genitourin. Cancer 17, e784–e792 (2019).
Giacalone, N. J. et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience. Eur. Urol. 71, 952–960 (2017).
Brausi, M. et al. Variability in the recurrence rate at first follow-up cystoscopy after tur in stage Ta t1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol. 41, 523–531 (2002).
Holzbeierlein, J. M. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J. Urol. 211, 533–538 (2024).
Cumberbatch, M. G. K. et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur. Urol. 73, 925–933 (2018).
Yanagisawa et al. Repeat transurethral resection for non-muscle-invasive bladder cancer: an updated systematic review and meta-analysis in the contemporary era. Eur. Urol. Focus 10, 41–56 (2023).
Divrik, R. T., Şahin, A. F., Yildirim, Ü., Altok, M. & Zorlu, F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur. Urol. 58, 185–190 (2010).
D’Andrea, D. et al. En bloc versus conventional resection of primary bladder tumor (eBLOC): a prospective, multicenter, open-label, phase 3 randomized controlled trial. Eur. Urol. Oncol. 6, 508–515 (2023).
Suarez-Ibarrola, R. et al. Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. BJU Int. 123, 646–650 (2019).
Mariappan, P. et al. Enhanced quality and effectiveness of transurethral resection of bladder tumour in non-muscle-invasive bladder cancer: a multicentre real-world experience from Scotland’s quality performance indicators programme. Eur. Urol. 78, 520–530 (2020).
Krieg, R. C., Messmann, H., Rauch, J., Seeger, S. & Knuechel, R. Metabolic characterization of tumor cell-specific protoporphyrin Ix accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem. Photobiol. 76, 518–525 (2007).
Lange, N. et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br. J. Cancer 80, 185–193 (1999).
Article CAS PubMed PubMed Central Google Scholar
Kriegmair, M. et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J. Urol. 155, 105–109 (1996).
Article CAS PubMed Google Scholar
Burger, M. et al. Photodynamic diagnosis of non–muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur. Urol. 64, 846–854 (2013).
Daneshmand, S. et al. Blue light cystoscopy for the diagnosis of bladder cancer: results from the US prospective multicenter registry. Urol. Oncol. 36, 361.e1–361.e6 (2018).
Chappidi, M. R. et al. Utility of blue light cystoscopy for post-bacillus Calmette-Guérin bladder cancer recurrence detection: implications for clinical trial recruitment and study comparisons. J. Urol. 207, 534–540 (2022).
Daneshmand, S. et al. Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase III, comparative, multicenter study. J. Urol. 199, 1158–1165 (2018).
Yuan, H. et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS ONE 8, e74142 (2013).
Maisch, P. et al. Blue vs white light for transurethral resection of non‐muscle‐invasive bladder cancer: an abridged Cochrane Review. BJU Int. 130, 730–740 (2022).
Veeratterapillay, R. et al. Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer. Eur. Urol. Open. Sci. 31, 17–27 (2021).
Article PubMed PubMed Central Google Scholar
Heer, R. et al. A randomized trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer. NEJM Evid. 1, EVIDoa2200092 (2022).
de Angelis, M., Briganti, A., Montorsi, F. & Moschini, M. Re: a randomized trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer. Eur. Urol. 83, 477–478 (2023).
St-Laurent, M. P., Suderman, J. & Black, P. C. Re: a randomized trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer. Eur. Urol. 83, 298–299 (2023).
Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J. Urol. 196, 1021–1029 (2016).
Babjuk, M. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) — 2019 update. Eur. Urol. 76, 639–657 (2019).
Article CAS PubMed Google Scholar
Flaig, T. W. et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 18, 329–354 (2020).
Klaassen, Z. et al. Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. Can. Urol. Assoc. J. 11, 173 (2017).
Article PubMed PubMed Central Google Scholar
Garfield, S. S., Gavaghan, M. B., Armstrong, S. O. & Jones, J. S. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can. J. Urol. 20, 6682–6689 (2013).
Williams, S. B., Gavaghan, M. B., Fernandez, A., Daneshmand, S. & Kamat, A. M. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer. Urol. Oncol. Semin. Orig. Investig. 40, 10.e7–10.e12 (2022).
Gono, K. et al. Appearance of enhanced tissue features in narrow-band endoscopic imaging. J. Biomed. Opt. 9, 568 (2004).
留言 (0)